Expression Biomarkers of Pharmacological Treatment Outcomes in Women with Unipolar and Bipolar Depression

Abstract

Introduction This study aimed to find the expression biomarkers of pharmacological treatment response in a naturalistic hospital setting. Through gene expression profiling, we were able to find differentially-expressed genes (DEGs) in unipolar (UD) and bipolar (BD) depressed women.

Methods We performed gene expression profiling in hospitalized women with unipolar (n=24) and bipolar depression (n=32) who achieved clinical improvement after pharmacological treatment (without any restriction). To identify DEGs in peripheral blood mononuclear cells (PBMCs), we used the SurePrint G3 Microarray and GeneSpring software.

Results After pharmacological treatment, UD and BD varied in the number of regulated genes and ontological pathways. Also, the pathways of neurogenesis and synaptic transmission were significantly up-regulated. Our research focused on DEGs with a minimum fold change (FC) of more than 2. For both types of depression, 2 up-regulated genes, OPRM1 and CELF4 (p=0.013), were significantly associated with treatment response (defined as a 50% reduction on the Hamilton Depression Rating Scale [HDRS]). We also uncovered the SHANK3 (p=0.001) gene that is unique for UD and found that the RASGRF1 (p=0.010) gene may be a potential specific biomarker of treatment response for BD.

Conclusion Based on transcriptomic profiling, we identified potential expression biomarkers of treatment outcomes for UD and BD. We also proved that the Ras-GEF pathway associated with long-term memory, female stress response, and treatment response modulation in animal studies impacts treatment efficacy in patients with BD. Further studies focused on the outlined genes may help provide predictive markers of treatment outcomes in UD and BD.

Key words

transcriptomic profile - ontology analysis - unipolar depression - bipolar depression - pharmacological treatment

Publication History

Received: 10 February 2021
Received: 05 May 2021

Accepted: 05 July 2021

Article published online:
01 September 2021

• References

• 1 Malhi GS, Mann JJ. Depression. Lancet 2018; 392: 2299-2312
• 2 Rybakowski JK. Bipolarity and inadequate response to antidepressant drugs: clinical and psychopharmacological perspective. J Affect Disord 2012; 136: e13-e19
• 3 Santarsieri D, Schwartz TL. Antidepressant efficacy and side-effect burden: A quick guide for clinicians. Drugs Context 2015; 4: 212290
• 4 Bradley P, Shiekh M, Mehra V. et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J Psychiatr Res 2018; 96: 100-107
• 5 Relling MV, Klein TE, Gammal RS. et al. The Clinical Pharmacogenetics Implementation Consortium: 10 years later. Clin Pharmacol Ther 2020; 107: 171-175
• 6 van Schaik RHN, Muller DJ, Serretti A. et al. Pharmacogenetics in psychiatry: An update on clinical usability. Front Pharmacol 2020; 11: 575540
• 7 Kuehner C. Why is depression more common among women than among men?. Lancet Psychiatry 2017; 4: 146-158
• 8 Young EA, Kornstein SG, Marcus SM. et al. Sex differences in response to citalopram: A STAR*D report. J Psychiatr Res 2009; 43: 503-511
• 9 LeGates TA, Kvarta MD, Thompson SM. Sex differences in antidepressant efficacy. Neuropsychopharmacology 2019; 44: 140-154
• 10 Labonte B, Engmann O, Purushothaman I. et al. Sex-specific transcriptional signatures in human depression. Nat Med 2017; 23: 1102-1111
• 11 Seney ML, Huo Z, Cahill K. et al. Opposite molecular signatures of depression in men and women. Biol Psychiatry 2018; 84: 18-27
• 12 Bagot RC, Cates HM, Purushothaman I. et al. Ketamine and imipramine reverse transcriptional signatures of susceptibility and induce resilience-specific gene expression profiles. Biol Psychiatry 2017; 81: 285-295
• 13 Grzenda A, Siddarth P, Laird KT. et al. Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression. Mol Psychiatry 2020; doi:10.1038/s41380-020-0752-2
• 14 Tansey KE, Guipponi M, Hu X. et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry 2013; 73: 679-682
• 15 Bhak Y, Jeong HO, Cho YS. et al. Depression and suicide risk prediction models using blood-derived multi-omics data. Transl Psychiatry 2019; 9: 262
• 16 Dmitrzak-Weglarz M, Szczepankiewicz A, Rybakowski J. et al. Transcriptomic profiling as biological markers of depression — a pilot study in unipolar and bipolar women. World J Biol Psychiatry 2021; 27: 1-13 doi:10.1080/15622975.2021.1907715
• 17 Cross-Disorder Group of the Psychiatric Genomics Consortium. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell 2019; 179: 1469-1482.e11
• 18 Blackburn TP. Depressive disorders: treatment failures and poor prognosis over the last 50 years. Pharmacol Res Perspect 2019; 7: e00472
• 19 Zhao L, Han G, Zhao Y. et al. Gender differences in depression: evidence from genetics. Front Genet 2020; 11: 562316
• 20 First MB, Spitzer RL, Gibbon M. et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, D.C.: American Psychiatric Press;; 1996
• 21 McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991; 48: 764-770
• 22 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
• 23 Rybakowski JK. Meaningful aspects of the term ‘mood stabilizer’. Bipolar Disord 2018; 20: 391-392
• 24 Ishii S, Karlamangla AS, Bote M. et al. Gender, obesity and repeated elevation of C-reactive protein: Data from the CARDIA cohort. PLoS One 2012; 7: e36062
• 25 Gautam A, Donohue D, Hoke A. et al. Investigating gene expression profiles of whole blood and peripheral blood mononuclear cells using multiple collection and processing methods. PLoS One 2019; 14: e0225137
• 26 Schwochow D, Serieys LE, Wayne RK. et al. Efficient recovery of whole blood RNA — a comparison of commercial RNA extraction protocols for high-throughput applications in wildlife species. BMC Biotechnol 2012; 12: 33
• 27 https://www.thermofisher.com/pl/en/home/references/protocols/nucleic-acid-purification-and-analysis/rna-protocol/alternative-protocol-extraction-of-rna-from-cells-captured-on-leukolock-filters-using-tri-reagent.html
• 28 Schroeder A, Mueller O, Stocker S. et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006; 7: 3
• 29 Dalman MR, Deeter A, Nimishakavi G. et al. Fold change and p-value cutoffs significantly alter microarray interpretations. BMC Bioinformatics 2012; 13: S11
• 30 Cheng C, Pounds S. False discovery rate paradigms for statistical analyses of microarray gene expression data. Bioinformation 2007; 1: 436-446
• 31 Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57
• 32 Bilska K, Pawlak J, Kapelski P. et al. Differences in the clinical picture in women with a depressive episode in the course of unipolar and bipolar disorder. J Clin Med 2021; 10: 676 doi: 10.3390/jcm10040676
• 33 Rybakowski J, Cubala WJ, Galecki P. et al. Recommendations of the Polish Psychiatric Association regarding the treatment of affective disorders in women of childbearing age. Part II: bipolar disorder. Psychiatr Pol 2019; 53: 263-276
• 34 Samochowiec J, Rybakowski J, Galecki P. et al. Recommendations of the Polish Psychiatric Association for treatment of affective disorders in women of childbearing age. Part I: treatment of depression. Psychiatr Pol 2019; 53: 245-262
• 35 Swiecicki L. Pharmacotherapy of depression in bipolar disorder. Psychiatry Res 2014; 11: 71-80
• 36 https://www.genecards.org/cgi-bin/carddisp.pl?gene = SHANK3&keywords = SHANK3
• 37 Han K, Holder JL, Schaaf CP. et al. SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature 2013; 503: 72-77
• 38 Ortiz R, Niciu MJ, Lukkahati N. et al. Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. J Affect Disord 2015; 172: 307-311
• 39 Manyes L, Holst S, Lozano M. et al. Spatial learning and long-term memory impairments in RasGrf1 KO, Pttg1 KO, and double KO mice. Brain Behav 2018; 8: e01089
• 40 Cheng Y, An Q, Wang J. et al. RasGRF1 participates in the protective effect of tanshinone IIA on depressive like behaviors of a chronic unpredictable mild stress induced mouse model. Gene 2020; 754: 144817
• 41 Jin SX, Dickson DA, Maguire J. et al. RASGRF1 in CRF cells controls the early adolescent female response to repeated stress. J Endocrinol 2020; 245: 397-410
• 42 Fabbri C, Serretti A. Genetics of long-term treatment outcome in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2016; 65: 17-24
• 43 Wagnon JL, Briese M, Sun W. et al. CELF4 regulates translation and local abundance of a vast set of mRNAs, including genes associated with regulation of synaptic function. PLoS Genet 2012; 8: e1003067
• 44 Barone R, Fichera M, De Grandi M. et al. Familial 18q12.2 deletion supports the role of RNA-binding protein CELF4 in autism spectrum disorders. Am J Med Genet A 2017; 173: 1649-1655
• 45 Smith DJ, Escott-Price V, Davies G. et al. Genome-wide analysis of over 106 000 individuals identifies 9 neuroticism-associated loci. Mol Psychiatry 2016; 21: 749-757
• 46 https://www.genecards.org/cgi-bin/carddisp.pl?gene=OPRM1
• 47 Jacobson ML, Wulf HA, Browne CA. et al. Opioid modulation of cognitive impairment in depression. Prog Brain Res 2018; 239: 1-48
• 48 Browne CA, Lucki I. Targeting opioid dysregulation in depression for the development of novel therapeutics. Pharmacol Ther 2019; 201: 51-76